Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISM8969 in Healthy Adults, Elderly, and Obese Participants at Risk of Cardiovascular Disease
NCT07581431Phase 1Recruiting
- Sponsor
- Insilico Medicine
- Start
- Jun 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ISM8969 in obesity (3 arms), sponsored by Insilico Medicine. Primary endpoints: Incidence of Adverse Events, Number of Participants with Clinical Laboratory Abnormalities, and Abnormalities in Vital Signs, Physical Examinations, 12-lead ECG and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
ISM8969
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07581431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581431.